AR037778A1 - Suplementacion mediada por plasmido para el tratamiento de sujetos cronicamente enfermos - Google Patents
Suplementacion mediada por plasmido para el tratamiento de sujetos cronicamente enfermosInfo
- Publication number
- AR037778A1 AR037778A1 ARP020104785A ARP020104785A AR037778A1 AR 037778 A1 AR037778 A1 AR 037778A1 AR P020104785 A ARP020104785 A AR P020104785A AR P020104785 A ARP020104785 A AR P020104785A AR 037778 A1 AR037778 A1 AR 037778A1
- Authority
- AR
- Argentina
- Prior art keywords
- seqid
- nucleic acid
- ghrh
- expression construct
- animal
- Prior art date
Links
- 230000009469 supplementation Effects 0.000 title abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 10
- 238000000034 method Methods 0.000 abstract 9
- 108020004707 nucleic acids Proteins 0.000 abstract 8
- 102000039446 nucleic acids Human genes 0.000 abstract 8
- 241001465754 Metazoa Species 0.000 abstract 7
- 102100022831 Somatoliberin Human genes 0.000 abstract 7
- 101710142969 Somatoliberin Proteins 0.000 abstract 7
- 235000001014 amino acid Nutrition 0.000 abstract 5
- 229940024606 amino acid Drugs 0.000 abstract 5
- 150000001413 amino acids Chemical class 0.000 abstract 5
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 206010006895 Cachexia Diseases 0.000 abstract 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 2
- 235000004279 alanine Nutrition 0.000 abstract 2
- 208000007502 anemia Diseases 0.000 abstract 2
- 230000006866 deterioration Effects 0.000 abstract 2
- 102000034356 gene-regulatory proteins Human genes 0.000 abstract 2
- 108091006104 gene-regulatory proteins Proteins 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 1
- 101150102363 Ghrh gene Proteins 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 abstract 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 229960001230 asparagine Drugs 0.000 abstract 1
- 235000009582 asparagine Nutrition 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000004520 electroporation Methods 0.000 abstract 1
- 230000012010 growth Effects 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 229960000310 isoleucine Drugs 0.000 abstract 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 230000001151 other effect Effects 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
- 239000004474 valine Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Composiciones y métodos de suplementación mediada por plásmido. Las composiciones y métodos son útiles para retrasar el crecimiento de un tumor y retrasar la caquexia, deterioro, anemia y otros efectos que están comúnmente asociados en los animales portadores de cáncer. La realización se lleva a cabo liberando una cantidad efectiva de una construcción de expresión de ácido nucleico que codifica una GHRH o un equivalente biológico funcional de la misma dentro del tejido de un animal y permitiendo la expresión en el animal del gen codificado. Por ejemplo, cuyo tales secuencias de ácido nucleico son liberados dentro de células específicas del tejido animal específico, se lleva a cabo la expresión constitutiva. Además, se puede llevar a cabo la regulación externa del gen de GHRH o del equivalente biológico funcional utilizando promotores inducibles que son regulados por moléculas interruptoras moleculares, las cuales son incorporadas en el animal. El método preferido para liberar la secuencia de ácido nucleico codificante constitutiva o inducible de GHRH o del equivalente biológico funcional de la misma es directamente dentro de las células del animal mediante el proceso de electroporación in vivo. Además, un tratamiento para retardar el crecimiento del tumor y retrasar la caquexia o los efectos del deterioro que están comúnmente asociados con los tumores, se lleva a cabo mediante la liberación dentro del animal de GHRH recombinante o el equivalente biológico. Reivindicación 4: El método de la reivindicación 1, en donde la construcción de expresión de ácido nucleico comprende la SeqID N°: 11, SeqID N°: 12, SeqID N°: 13, SeqID N°: 14, SeqID N°:17, SeqID N°: 18, SeqID N°:19, SeqID N°: 20 ó SeqID N°: 21. Reivindicación 8: El método de la reivindicación 1, en donde la liberación dentro de las células del sujeto de la construcción de expresión de ácido nucleico inicia la expresión de la GHRH codificada o el equivalente biológico funcional de la misma. Reivindicación 12: El método de la reivindicación 8, en donde la GHRH codifica o el equivalente biológico funcional codificado de la misma es de la fórmula (SeqID N°: 6): X-1-X2-DAIFTNSYRKVL-X3-QLSARKLLQDI-X4-X5-RQQGERNQEQGA-OH en donde la fórmula tiene las siguientes características: X-1 es isómero -L o -D de un aminoácido tirosina ("Y"), o histidina ("H"); X2 es un isómero -L o -D del aminoácido alanina ("A"), valina ("V"), o isoleucina ("I"); X3 es un isómero -L o -D del mismo aminoácido alanina ("A") o glicina ("G"); X4 es un isómero -L o -D del aminoácido metionina ("M"), o leucina ("L"); X5 es un isómero -L o -D del aminoácido serina ("S") o asparragina ("N"); o una combinación de los mismos. Reivindicación 13: El método de la reivindicación 1, en donde la construcción de expresión de ácido nucleico codifica un polipéptido de una secuencia que comprende la SeqID N°: 1, SeqID N°: 2, SeqID N°: 3, o SeqID N°: 4. Reivindicación 15: El método de tratamiento de la anemia en un sujeto, que comprende: (a) liberar dentro de las células del sujeto una cantidad específica de una primera construcción de expresión de ácido nucleico, y una cantidad específica de una segunda construcción de expresión de ácido nucleico; en donde la primer construcción de expresión de ácido nucleico codifica a la hormona liberadora de la hormona de crecimiento ("GHRH") o un equivalente biológico funcional de la misma; y en donde la segunda construcción de expresión de ácido nucleico tiene una región codificante de una proteína reguladora; y (b) liberar una molécula interruptor molecular dentro del sujeto, en donde la molécula interruptor molecular gobierna la activación de al proteína reguladora.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33961001P | 2001-12-11 | 2001-12-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR037778A1 true AR037778A1 (es) | 2004-12-01 |
Family
ID=23329825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020104785A AR037778A1 (es) | 2001-12-11 | 2002-12-10 | Suplementacion mediada por plasmido para el tratamiento de sujetos cronicamente enfermos |
Country Status (11)
Country | Link |
---|---|
US (2) | US7241744B2 (es) |
EP (1) | EP1465654B1 (es) |
CN (1) | CN1615151A (es) |
AR (1) | AR037778A1 (es) |
AU (1) | AU2002357143B2 (es) |
BR (1) | BR0214869A (es) |
CA (1) | CA2469310C (es) |
MX (1) | MXPA04005713A (es) |
MY (1) | MY142457A (es) |
TW (1) | TW200301778A (es) |
WO (1) | WO2003049700A2 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1578901A4 (en) * | 2001-09-07 | 2006-03-29 | Baylor College Medicine | LINEAR DNA FRAGMENTS FOR GENE EXPRESSION |
CN100417419C (zh) * | 2001-10-26 | 2008-09-10 | 贝勒医学院 | 改变个体的瘦体重和骨特性的组合物和方法 |
AR037778A1 (es) * | 2001-12-11 | 2004-12-01 | Advisys Inc | Suplementacion mediada por plasmido para el tratamiento de sujetos cronicamente enfermos |
TW200307749A (en) * | 2002-02-07 | 2003-12-16 | Baylor College Medicine | Modified pituitary gland development in offspring from expectant mother animals treated with growth hormone releasing hormone therapy |
CN1662261A (zh) * | 2002-05-28 | 2005-08-31 | 阿德维希斯公司 | 通过多聚-l-谷氨酸(“plg”)系统增加核酸构建体的体内递送 |
TWI290174B (en) * | 2002-11-04 | 2007-11-21 | Advisys Inc | Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells |
TW200424214A (en) * | 2003-04-21 | 2004-11-16 | Advisys Inc | Plasmid mediated GHRH supplementation for renal failures |
US7468273B2 (en) | 2003-05-01 | 2008-12-23 | Meial Limited | Canine GHRH gene, polypeptides and methods of use |
CA2575926C (en) * | 2003-08-04 | 2014-02-25 | Advisys, Inc. | Canine specific growth hormone releasing hormone |
CN101027081A (zh) * | 2004-07-23 | 2007-08-29 | 阿德维希斯公司 | 生长激素释放激素增强疫苗接种应答 |
US7846720B2 (en) * | 2005-01-26 | 2010-12-07 | Vgx Pharmaceuticals, Inc. | Optimized high yield synthetic plasmids |
DE602006013117D1 (de) | 2005-04-25 | 2010-05-06 | Merial Ltd | Nipah-virus-impfstoffe |
EP1951751B1 (en) | 2005-11-14 | 2017-11-01 | Merial, Inc. | Gene therapy for renal failure |
US7771995B2 (en) | 2005-11-14 | 2010-08-10 | Merial Limited | Plasmid encoding human BMP-7 |
US8980249B2 (en) | 2010-06-03 | 2015-03-17 | University Of Miami | Agonists of growth hormone releasing hormone as effectors for survival and proliferation of pancreatic islets |
US9216213B2 (en) | 2011-04-20 | 2015-12-22 | Merial, Inc. | Adjuvanted rabies vaccine with improved viscosity profile |
US8993316B2 (en) | 2011-11-16 | 2015-03-31 | Brian P. Hanley | Methods and compositions for gene therapy and GHRH therapy |
US9079974B2 (en) * | 2011-12-21 | 2015-07-14 | The University Of Miami | GH-RH analogs with potent agonistic effects |
WO2013138776A1 (en) | 2012-03-16 | 2013-09-19 | Merial Limited | Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g |
EP2935317B1 (en) | 2012-12-21 | 2019-03-27 | University of Miami | Ghrh agonists for islet cell transplantation and function and the treatment of diabetes |
EP2934565B1 (en) | 2012-12-21 | 2019-03-13 | University of Miami | Ghrh agonists for the treatment of ischemic disorders |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4223020A (en) | 1979-03-30 | 1980-09-16 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
US4223019A (en) * | 1979-03-30 | 1980-09-16 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
US4226857A (en) * | 1979-03-30 | 1980-10-07 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
US4224316A (en) | 1979-03-30 | 1980-09-23 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
US4223021A (en) | 1979-03-30 | 1980-09-16 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
US4228158A (en) * | 1979-03-30 | 1980-10-14 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
US4228156A (en) * | 1979-03-30 | 1980-10-14 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
US4410512A (en) * | 1981-12-28 | 1983-10-18 | Beckman Instruments, Inc. | Combinations having synergistic pituitary growth hormone releasing activity |
NL8200523A (nl) | 1982-02-11 | 1983-09-01 | Univ Leiden | Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna. |
US5134120A (en) | 1984-08-03 | 1992-07-28 | Cornell Research Foundation, Inc. | Use of growth hormone to enhance porcine weight gain |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US5036045A (en) * | 1985-09-12 | 1991-07-30 | The University Of Virginia Alumni Patents Foundation | Method for increasing growth hormone secretion |
US4833166A (en) * | 1987-05-01 | 1989-05-23 | Grosvenor Clark E | Growth hormone releasing hormone complementary peptides |
US4839344A (en) * | 1987-06-12 | 1989-06-13 | Eastman Kodak Company | Polypeptide compounds having growth hormone releasing activity |
USRE33699E (en) | 1987-07-09 | 1991-09-24 | International Minerals & Chemical Corp. | Growth hormone-releasing factor analogs |
FR2622455B1 (fr) | 1987-11-04 | 1991-07-12 | Agronomique Inst Nat Rech | Application du facteur de stimulation de la secretion de l'hormone de croissance humaine, de ses fragments actifs et des analogues correspondants, pour augmenter la production laitiere et le poids des nouveau-nes chez les mammiferes |
US4952500A (en) | 1988-02-01 | 1990-08-28 | University Of Georgia Research Foundation, Inc. | Cloning systems for Rhodococcus and related bacteria |
US4956288A (en) | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
US5023322A (en) * | 1988-08-31 | 1991-06-11 | Mta Kutatas-Es Szervezetelemzo Intezete | Analogs of growth hormone releasing factor (GRF) and a method for the preparation thereof |
US5084442A (en) | 1988-09-06 | 1992-01-28 | Hoffmann-La Roche Inc. | Cyclic growth hormone releasing factor analogs and method for the manufacture thereof |
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5302523A (en) * | 1989-06-21 | 1994-04-12 | Zeneca Limited | Transformation of plant cells |
US7705215B1 (en) | 1990-04-17 | 2010-04-27 | Dekalb Genetics Corporation | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof |
US5550318A (en) | 1990-04-17 | 1996-08-27 | Dekalb Genetics Corporation | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof |
US5137872A (en) | 1989-09-18 | 1992-08-11 | Pitman-Moore, Inc. | Growth hormone-releasing factor analogs |
US5322783A (en) | 1989-10-17 | 1994-06-21 | Pioneer Hi-Bred International, Inc. | Soybean transformation by microparticle bombardment |
US5484956A (en) | 1990-01-22 | 1996-01-16 | Dekalb Genetics Corporation | Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin |
NZ238748A (en) | 1990-06-29 | 1993-09-27 | Hoffmann La Roche | Growth hormone releasing factor (grf) analogues |
US5486505A (en) * | 1990-07-24 | 1996-01-23 | Polygen Holding Corporation | Polypeptide compounds having growth hormone releasing activity |
US5384253A (en) * | 1990-12-28 | 1995-01-24 | Dekalb Genetics Corporation | Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes |
CA2084061A1 (en) | 1991-04-09 | 1992-10-10 | Arthur M. Felix | Growth hormone releasing factor analogs |
WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
US5663146A (en) * | 1991-08-22 | 1997-09-02 | Administrators Of The Tulane Educational Fund | Polypeptide analogues having growth hormone releasing activity |
US5610042A (en) | 1991-10-07 | 1997-03-11 | Ciba-Geigy Corporation | Methods for stable transformation of wheat |
US5925564A (en) * | 1991-11-06 | 1999-07-20 | Baylor College Of Medicine | Expression vector systems and method of use |
US5298422A (en) * | 1991-11-06 | 1994-03-29 | Baylor College Of Medicine | Myogenic vector systems |
JP3368603B2 (ja) * | 1992-02-28 | 2003-01-20 | オリンパス光学工業株式会社 | 遺伝子治療用処置具 |
US6033884A (en) | 1992-03-20 | 2000-03-07 | Baylor College Of Medicine | Nucleic acid transporter systems and methods of use |
EP1236473A3 (en) | 1992-04-03 | 2003-01-15 | The Regents Of The University Of California | Self-assembling polynucleotide delivery system |
AU685054C (en) | 1992-05-14 | 2003-02-27 | Baylor College Of Medicine | Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy |
DE69334225D1 (de) * | 1992-07-07 | 2008-07-31 | Japan Tobacco Inc | Verfahren zur transformation einer monokotyledon pflanze |
US5702932A (en) | 1992-07-20 | 1997-12-30 | University Of Florida | Microinjection methods to transform arthropods with exogenous DNA |
CA2140910C (en) | 1992-07-27 | 1999-03-23 | Jeffrey A. Townsend | An improved method of agrobacterium-mediated transformation of cultured soybean cells |
DE4228457A1 (de) | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
GB9222888D0 (en) | 1992-10-30 | 1992-12-16 | British Tech Group | Tomography |
US5439440A (en) * | 1993-04-01 | 1995-08-08 | Genetronics, Inc. | Electroporation system with voltage control feedback for clinical applications |
US5656610A (en) | 1994-06-21 | 1997-08-12 | University Of Southern California | Producing a protein in a mammal by injection of a DNA-sequence into the tongue |
FR2722208B1 (fr) | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
US5736524A (en) * | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
US5792747A (en) | 1995-01-24 | 1998-08-11 | The Administrators Of The Tulane Educational Fund | Highly potent agonists of growth hormone releasing hormone |
AU5441096A (en) | 1995-04-14 | 1996-10-30 | The Administrators Of The Tulane Eductional Fund | Analogs of growth hormone-releasing factor |
US5780448A (en) * | 1995-11-07 | 1998-07-14 | Ottawa Civic Hospital Loeb Research | DNA-based vaccination of fish |
US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
US5945100A (en) * | 1996-07-31 | 1999-08-31 | Fbp Corporation | Tumor delivery vehicles |
US6251433B1 (en) * | 1996-08-13 | 2001-06-26 | Chiron Corporation | Polycationic polymers |
US5981274A (en) | 1996-09-18 | 1999-11-09 | Tyrrell; D. Lorne J. | Recombinant hepatitis virus vectors |
US5704908A (en) * | 1996-10-10 | 1998-01-06 | Genetronics, Inc. | Electroporation and iontophoresis catheter with porous balloon |
JP2001511353A (ja) * | 1997-07-24 | 2001-08-14 | バレンティス・インコーポレーテッド | Ghrhの発現システムおよび使用法 |
US5994624A (en) * | 1997-10-20 | 1999-11-30 | Cotton Incorporated | In planta method for the production of transgenic plants |
US6194402B1 (en) * | 1998-09-02 | 2001-02-27 | Merck & Co., Inc. | Enhancement of return to independent living status with a growth hormone secretagogue |
CA2303702A1 (en) * | 1999-04-12 | 2000-10-12 | Pfizer Products Inc. | Growth hormone and growth hormone releasing hormone compositions |
PL366132A1 (en) * | 1999-07-26 | 2005-01-24 | Baylor College Of Medicine | Super-active porcine growth hormone releasing hormone analog |
AR037778A1 (es) * | 2001-12-11 | 2004-12-01 | Advisys Inc | Suplementacion mediada por plasmido para el tratamiento de sujetos cronicamente enfermos |
US7964196B2 (en) * | 2004-05-25 | 2011-06-21 | Chimeros, Inc. | Self-assembling nanoparticle drug delivery system |
US9302725B2 (en) | 2013-03-14 | 2016-04-05 | Bell Sports, Inc. | Locking rack system for bicycles |
WO2015178959A1 (en) | 2014-05-19 | 2015-11-26 | Felix Sorkin | Modified permanent cap |
-
2002
- 2002-12-10 AR ARP020104785A patent/AR037778A1/es not_active Application Discontinuation
- 2002-12-10 US US10/315,907 patent/US7241744B2/en not_active Expired - Lifetime
- 2002-12-10 MX MXPA04005713A patent/MXPA04005713A/es not_active Application Discontinuation
- 2002-12-10 TW TW091135752A patent/TW200301778A/zh unknown
- 2002-12-10 EP EP02804771.0A patent/EP1465654B1/en not_active Expired - Lifetime
- 2002-12-10 MY MYPI20024609A patent/MY142457A/en unknown
- 2002-12-10 WO PCT/US2002/039509 patent/WO2003049700A2/en not_active Application Discontinuation
- 2002-12-10 CN CNA02827105XA patent/CN1615151A/zh active Pending
- 2002-12-10 BR BR0214869-2A patent/BR0214869A/pt not_active Application Discontinuation
- 2002-12-10 CA CA2469310A patent/CA2469310C/en not_active Expired - Lifetime
- 2002-12-10 AU AU2002357143A patent/AU2002357143B2/en not_active Expired
-
2007
- 2007-03-21 US US11/726,291 patent/US8178504B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA2469310A1 (en) | 2003-06-19 |
US7241744B2 (en) | 2007-07-10 |
CN1615151A (zh) | 2005-05-11 |
US8178504B2 (en) | 2012-05-15 |
EP1465654A4 (en) | 2007-08-29 |
MY142457A (en) | 2010-11-30 |
WO2003049700B1 (en) | 2003-10-30 |
WO2003049700A2 (en) | 2003-06-19 |
TW200301778A (en) | 2003-07-16 |
CA2469310C (en) | 2013-01-29 |
AU2002357143B2 (en) | 2009-07-30 |
MXPA04005713A (es) | 2005-06-06 |
US20090170748A1 (en) | 2009-07-02 |
EP1465654B1 (en) | 2015-02-25 |
BR0214869A (pt) | 2005-03-08 |
EP1465654A2 (en) | 2004-10-13 |
WO2003049700A3 (en) | 2003-09-18 |
US20040057941A1 (en) | 2004-03-25 |
AU2002357143A1 (en) | 2003-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR037778A1 (es) | Suplementacion mediada por plasmido para el tratamiento de sujetos cronicamente enfermos | |
DE60327786D1 (de) | Kdr-peptide und diese enthaltende impfstoffe | |
Del Sal et al. | cDNA cloning of the neutrophil bactericidal peptide indolicidin | |
DK1442058T3 (da) | Peptider der er effektive til behandling af tumorer og andre tilstande der kræver fjernelse eller destruktion af celler | |
EA200800368A1 (ru) | Гликозилированный il-7, получение и применение | |
US3948875A (en) | Process for the preparation of epidermal growth factor and new derivative using cross-linked polyacrylamide gel at a pH of 1-3 | |
ATE430161T1 (de) | Peptid aus hsp70 welches nk zellaktivtät stimuliert und seine verwendung | |
KR101807593B1 (ko) | 흉터 최소화 상처 재생 촉진용 재조합 폴리펩타이드 및 이를 포함하는 생체 접착 소재 | |
Cordingley | Trematode eggshells: novel protein biopolymers | |
AR037038A1 (es) | Una composicion y metodo para alterar la masa corporal magra y las propiedades oseas en un sujeto | |
DK1201137T3 (da) | Cystein-/glycinrige peptider | |
DK1264599T3 (da) | TNF-afledte peptider til anvendelse i behandling af ödem | |
ATE420191T1 (de) | Promotoren zur expression im modifizierten vacciniavirus ankara | |
AR010337A1 (es) | Acido nucleico aislado, molecula de acido nucleico, sonda, vector de expresion recombinante, celula, metodo para producir un polipeptido de h.pylori, metodo para detectar la presencia de un acido nucleico helicobacter, polipeptido de h.pylori aislado, proteina de fusion, formulacion para vacuna | |
EP0236977A3 (en) | Bovine virus diarrhea and hog cholera vaccines | |
PE20212072A1 (es) | Composiciones utiles en el tratamiento de la enfermedad de krabbe | |
AR045000A1 (es) | Gen y proteina de eimeria , y su uso | |
FI20050753A0 (fi) | Uudet peptidit | |
ATE325812T1 (de) | Menschliches, gebärmutterkrebs-spezifisches suppressorprotein, für das protein kodieres polynukleotid, mit dem polynukleotid transformierte zelle und verfahren zur unterdrückung der proliferation von krebszellen unter verwendung des expressionsvektors | |
EP0361956A3 (en) | Increased expression of small molecular weight recombinant proteins | |
AR029130A1 (es) | Gen enzimatico y sus productos de expresion | |
ATE423200T1 (de) | Neues plexin-polypeptid, dieses codierende dna und verwendung davon | |
DE50310131D1 (de) | Peptide mit hohem cysteingehalt | |
CY1109617T1 (el) | Ενα πεπτιδιο hsp70 που διεγειρει τη δραστηριοτητα φυσικων φονικων κυτταρων (νκ) και χρησεις αυτου |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |